Pharmacy,
Год журнала:
2024,
Номер
12(6), С. 171 - 171
Опубликована: Ноя. 20, 2024
Objective:
This
study
assesses
the
association
of
metabolic
drugs
(specifically
hypoglycemic
and
hypolipemic
agents)
with
cardiovascular
diseases
(CVD)
among
Lebanese
population
patients’
subgroups.
Methods:
A
nationwide
cross-sectional
retrospective
was
carried
out
in
Lebanon.
The
survey
collected
information
on
sociodemographic
characteristics,
lifestyles,
comorbidities,
medication
use.
Logistic
regression
models
were
employed
to
analyze
data
determine
associations
between
CVD
drugs.
Stratification
analyses
performed
based
diabetes
dyslipidemia
status.
Results:
found
significant
2048
participants.
Higher
scores
Mediterranean
Diet
Score
(LMDS;
ORa
=
1.06),
hypertension
(ORa
1.71),
1.75),
1.89),
family
history
1.58),
smoking
(previous:
1.63,
current:
2.15)
linked
increased
odds.
income
(intermediate:
0.64,
high:
0.40)
inversely
related
it.
subsequent
model
that
included
lipid-lowering
medications
yielded
similar
results.
However,
neither
nor
demonstrated
a
risk.
third
conducted
by
taking
classes
as
an
independent
variable.
Also,
result
revealed
all
not
associated
risk
CVD.
LMDS
factors
both
groups.
Among
non-diabetic
participants,
2.40),
current
2.28),
higher
0.57,
0.62)
people
diabetes,
2.69)
odds,
while
being
employer
0.49)
lowered
showed
consistent
factors,
1.07),
2.14),
1.79),
previous
1.95)
without
dyslipidemia.
Being
female
0.52)
having
lower
odds
those
Subgroup
significantly
patients
or
hyperlipidemia.
Conclusions:
study’s
findings
highlight
importance
addressing
modifiable
socioeconomic
reduce
burden
Targeted
interventions
longitudinal
research
are
necessary
optimize
preventive
strategies
improve
management
individuals
using
agents
low-
medium-income
countries.
Biomedicines,
Год журнала:
2025,
Номер
13(2), С. 359 - 359
Опубликована: Фев. 4, 2025
The
investigation
of
biomarkers
for
metabolic
diseases
such
as
type
2
diabetes
mellitus
(T2DM)
and
dysfunction-associated
steatohepatitis
(MASH)
reveals
their
potential
advancing
disease
treatment
addressing
notable
overlap.
connection
between
MASH,
obesity,
T2DM
highlights
the
need
an
integrative
management
approach
mechanisms
like
insulin
resistance
chronic
inflammation.
Obesity
contributes
significantly
to
development
MASH
through
lipid
dysregulation,
resistance,
Selective
biomarker
targeting
offers
a
valuable
strategy
detecting
these
comorbidities.
Biomarkers
CRP,
IL-6,
TNF-α
serve
indicators
inflammation,
while
HOMA-IR,
fasting
insulin,
HbA1c
are
essential
evaluating
resistance.
Additionally,
triglycerides,
LDL,
HDL
crucial
comprehending
dysregulation.
Despite
growing
importance
digital
biomarkers,
challenges
in
research
methodologies
sample
variability
persist,
necessitating
further
studies
validate
diagnostic
tools
improve
health
interventions.
Future
opportunities
include
developing
non-invasive
panels,
using
multiomics,
machine
learning
enhance
prognoses
accuracy
therapeutic
outcomes.
Atherosclerotic
cardiovascular
diseases
(ASCVDs)
remain
a
leading
cause
of
mortality,
with
early
cholesterol
control
being
pivotal
in
mitigating
long-term
risk.
Recent
findings
suggest
that
intermittent
hyperlipidemia,
characterized
by
oscillatory
exposure,
uniquely
accelerates
atherosclerosis
compared
to
continuous
high-fat
diets.
This
review
synthesizes
emerging
evidence
on
hyperlipidemia's
impact
atherogenesis,
emphasizing
macrophage
dysfunction,
autophagy
impairment,
and
efferocytosis
deficits.
We
also
discuss
critical
gaps,
including
sex-specific
differences,
gut-microbiota
interactions,
the
influence
maternal
hypercholesterolemia.
Notably,
recent
insights
into
IL-1β-dependent
neutrophil
reprogramming
under
diets
reveal
novel
inflammatory
mechanisms
driving
plaque
destabilization.
Addressing
these
gaps
will
advance
our
understanding
atherogenesis
guide
development
innovative
prevention
strategies
therapeutic
interventions.
International Journal of Food Science,
Год журнала:
2025,
Номер
2025(1)
Опубликована: Янв. 1, 2025
Fermentation
preserves
and
enhances
food
properties,
but
consuming
locally
fermented
foods
can
cause
health
issues
like
flatulence,
gastrointestinal
disorders,
kidney
stones,
sometimes
death.
This
study
evaluated
the
biochemical,
haematological,
histological
effects
of
supplementing
diets
with
Moringa
oleifera
seed
(FMS)
nonfermented
(NFMS)
in
healthy
albino
rats.
Male
rats
were
fed
containing
10%,
20%,
30%
FMS
NFMS
for
14
days.
No
significant
changes
observed
body
weight
or
organ/body
ratios.
However,
platelet
count
increased
significantly
(p
<
0.05)
at
higher
supplementation
levels,
suggesting
enhanced
haemostatic
activity.
While
haematological
parameters
remained
stable,
20%
urea
creatinine
indicating
potential
renal
stress.
Histological
analysis
showed
mild
alterations
more
pronounced
NFMS-fed
mitigated
antinutrient
effects,
enhancing
safety.
are
safe
up
to
inclusion,
applications
human
nutrition
functional
development.
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Окт. 17, 2024
The
association
and
co-isolation
of
low-density
lipoproteins
(LDL)
extracellular
vesicles
(EVs)
have
been
shown
in
blood
plasma.
Here
we
explore
this
relationship
to
better
understand
the
role
EVs
atherogenesis.
Frontiers in Cardiovascular Medicine,
Год журнала:
2025,
Номер
11
Опубликована: Янв. 6, 2025
Obesity
is
one
of
the
major
global
health
concerns
21st
century,
associated
with
many
comorbidities
such
as
type
2
diabetes
mellitus
(T2DM),
metabolic
dysfunction-associated
steatotic
liver
disease,
and
early
aggressive
atherosclerotic
cardiovascular
which
leading
cause
death
worldwide.
Bile
acids
(BAs)
incretins
are
gut
hormones
involved
in
digestion
absorption
fatty
acids,
insulin
secretion,
respectively.
In
recent
years
BAs
increasingly
recognized
key
signaling
molecules,
target
multiple
tissues
organs,
beyond
gastro-intestinal
system.
Moreover,
incretin-based
therapy
has
revolutionized
treatment
T2DM
obesity.
This
mini
review
highlights
current
knowledge
about
dysregulations
BA
homeostasis
obesity
a
special
focus
on
atherosclerosis
well
athero-modulating
roles
currently
available
therapies.
PLoS ONE,
Год журнала:
2025,
Номер
20(1), С. e0317202 - e0317202
Опубликована: Янв. 10, 2025
Modern
treatment,
a
healthy
diet,
and
physical
activity
routines
lower
the
risk
factors
for
metabolic
syndrome;
however,
this
condition
is
associated
with
all-cause
cardiovascular
mortality
worldwide.
This
investigation
involved
randomized
controlled
trial,
double-blind,
parallel
study.
Fifty-eight
participants
of
syndrome
according
to
inclusion
criteria
were
into
two
groups
given
probiotics
(
Lacticaseibacillus
paracasei
MSMC39-1
Bifidobacterium
animalis
TA-1)
(n
=
31)
or
placebo
27).
The
had
mean
age
42.29
±
7.39
43.89
7.54
years
in
groups,
respectively.
Stool
samples,
anthropometric
data,
blood
chemistries
taken
at
baseline
12
weeks.
primary
outcome
was
achieved
by
group
as
their
low-density
lipoprotein-cholesterol
level
dramatically
lowered
compared
(the
difference
39.97
26.83
mg/dl,
p-value
<0.001).
Moreover,
significant
reductions
body
weight,
mass
index,
waist
circumference,
systolic
pressure,
total
cholesterol
observed
volunteers
treated
placebo.
In
gut
microbiome
analysis,
results
showed
statistically
differences
beta
diversity
post-intervention
group.
Blautia
,
Roseburia
Collinsella
Ruminococcus
among
microbiomes
that
more
prevalent
addition,
exhibited
increases
predicted
functional
changes
ATP-binding
cassette
(ABC)
transporters,
well
ribonucleic
acid
transport,
biosynthesis
unsaturated
fatty
acids,
glycerophospholipid
metabolism,
pyruvate
metabolism.
conclusion,
research
demonstrated
L
.
B
TA-1
have
efficacy
syndrome.
Cardiovascular
diseases
(CVDs)
remain
the
leading
cause
of
mortality
worldwide,
highlighting
critical
need
for
effective
preventive
therapies.
Statins,
or
HMG-CoA
reductase
inhibitors,
are
widely
prescribed
their
ability
to
lower
low-density
lipoprotein
(LDL)
cholesterol
and
reduce
CV
risk.
This
systematic
review
evaluates
long-term
impact
statins
on
all-cause
across
diverse
populations,
including
those
with
chronic
kidney
disease,
heart
failure,
other
comorbid
conditions.
A
comprehensive
search
major
databases
identified
randomized
controlled
trials
large
observational
cohort
studies
follow-up
periods
exceeding
one
year.
Findings
demonstrated
significant
reductions
in
(hazard
ratio
(HR)
range:
0.38-0.76)
(HR
0.55-0.80)
statin
therapy,
particularly
among
high-risk
groups,
such
as
individuals
elevated
LDL-C
moderate
disease.
Additional
benefits
were
observed
preventing
adverse
cardiovascular
events
(MACEs).
Subgroup
analyses
revealed
variations
efficacy
based
age,
sex,
comorbidities,
type
dosage,
some
failure
obstructive
pulmonary
showing
limited
benefit.
Geographic
ethnic
diversity
underrepresented
included
studies,
data
effects
populations
advanced
renal
impairment
inflammatory
conditions
insufficient.
These
gaps
underscore
methodologically
robust
tailored
approaches
therapy
that
account
individual
patient
profiles,
comorbidities
demographic
factors.
Practical
steps
include
integrating
newer
lipid-lowering
agents
developing
personalized
treatment
protocols
maximize
minimize
risks.
reinforces
role
reducing
global
burden
CVDs
while
emphasizing
areas
future
research.